“Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s271, https://doi.org/10.25251/skin.7.supp.271.